Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephane Rinfret

Interventional Cardiology Gainesville, GA Medical Doctor

NPI 1679168470 CMS profile 9074952

200 S Enota Dr Ne Ste 100, Gainesville, GA 30501

Open in the dashboard

General payments

$71,713

251 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephane Rinfret of Gainesville, GA is reported in the CMS Open Payments database as having received $71,713 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,565 34
2024 General $10,712 32
2023 General $30,333 45
2022 General $17,993 84
2021 General $10,110 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephane Rinfret
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Stephane Rinfret were reported at $2,565. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Stephane Rinfret Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $10,110 $677 $233–$1,827 $132
2022 $17,993 $978 $333–$2,724 $149
2023 $30,333 $1,136 $382–$2,986 $160
2024 $10,712 $1,181 $395–$3,326 $164
2025 $2,565 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $16,931 28 payments
  2. Arrow International, Inc. $14,908 8 payments
  3. Medtronic, Inc. $13,321 64 payments
  4. Abiomed $12,556 20 payments
  5. Boston Scientific Corporation $7,212 73 payments
  6. Shockwave Medical, Inc $1,537 15 payments
  7. Abbott Laboratories $1,457 13 payments
  8. Philips Electronics North America Corporation $1,304 3 payments
  9. Asahi Intecc USA, Inc. $860 8 payments
  10. Edwards Lifesciences Corporation $346 2 payments
  11. Other $1,280 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $24,750 7 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,518 7 payments
  3. Food and Beverage $14,771 213 payments
  4. Travel and Lodging $7,874 23 payments
  5. Honoraria $7,800 1 payment
Products named General payments · program years 2021–2025
  1. Impella $12,344 16 payments
  2. RESOLUTE ONYX $8,464 27 payments
  3. GUIDELINER $4,876 6 payments
  4. TURNPIKE $4,430 3 payments
  5. GENERAL - VASCULAR ACCESS $4,000 2 payments
  6. Resolute $3,781 11 payments
  7. (9520) IGT Devices Undivided $1,154 2 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $966 8 payments
  9. OPTIS $765 5 payments
  10. ONYX FRONTIER $739 21 payments
  11. Other $9,915 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

74

Median for Cardiology: 2,533

Drug cost

$11,116

Median for Cardiology: $485,213

Branded share of claims

82.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 18 $10,374
Prasugrel Hcl Generic 13 $344
Clopidogrel Clopidogrel Bisulfate Brand 32 $343
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 11 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$81,339

Medicare's payments for the services billed

Medicare patients

436

Average age 75

Services billed

902

187 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Atrial fibrillation 48%
Arthritis 47%
Heart failure 46%
Chronic kidney disease 44%
Diabetes 39%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record